Immix Biopharma (IMMX) News Today → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free IMMX Stock Alerts $2.18 -0.06 (-2.68%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Decreases By 10.0%americanbankingnews.com - May 1 at 9:56 AMImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Drop in Short Interestamericanbankingnews.com - May 1 at 5:16 AMImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myelomafinanznachrichten.de - April 29 at 2:32 PMImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myelomaglobenewswire.com - April 29 at 9:39 AMImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Decrease in Short Interestmarketbeat.com - April 29 at 8:56 AMImmix Biopharma, Inc. (IMMX)finance.yahoo.com - April 18 at 11:00 PMImmix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United Statesfinanznachrichten.de - April 18 at 6:00 PMImmix Biopharma on Track to Dose NXC-201 Patients in United Statesglobenewswire.com - April 18 at 9:32 AMImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)globenewswire.com - April 15 at 9:36 AMIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023investorplace.com - April 2 at 8:06 AMImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trialglobenewswire.com - March 20 at 9:46 AMImmix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiativestockhouse.com - March 7 at 7:29 PMImmix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiativeglobenewswire.com - March 5 at 9:35 AMImmix Biopharma (IMMX) Price Target Increased by 27.27% to 14.28msn.com - February 24 at 11:20 PMIMMX Apr 2024 7.500 callfinance.yahoo.com - February 22 at 7:52 PMImmix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress Updatefinanznachrichten.de - February 21 at 2:15 PMImmix Biopharma 12 Month Review Progress Updatemarkets.businessinsider.com - February 21 at 2:15 PMImmix Biopharma 12 Month Review Progress Updatefinance.yahoo.com - February 21 at 2:15 PMImmix Biopharma 12 Month Review Progress Updateglobenewswire.com - February 21 at 9:31 AMIMMX Aug 2024 2.500 callfinance.yahoo.com - February 13 at 7:56 AMImmix Biopharma Announces Closing of $15 Million Public Offering of Common Stockfinance.yahoo.com - February 8 at 7:18 PMImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosisfinanznachrichten.de - February 8 at 2:17 PMImmix Biopharma Signs Definitive $15M Titan Partnership Dealmarkets.businessinsider.com - February 7 at 12:40 PMImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosisfinance.yahoo.com - February 7 at 12:40 PMImmix Biopharma Suspends Stock Offering Pending New Prospectusmsn.com - February 6 at 10:20 AMImmix Biopharma Announces Pricing of $15 Million Public Offering of Common Stockfinance.yahoo.com - February 5 at 11:42 PMImmix Biopharma Announces Proposed Public Offering of Common Stockfinance.yahoo.com - February 5 at 6:41 PMmarketbeat.com - February 5 at 3:35 PMmarketbeat.com - February 5 at 3:35 PMImmix Biopharma Reveals FDA Labeling Change Notification For CAR-T Productsmarkets.businessinsider.com - January 24 at 7:27 PMImmix Biopharma, Inc.: Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Productsfinanznachrichten.de - January 24 at 2:27 PMImmix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Productsfinance.yahoo.com - January 24 at 2:27 PMImmix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Increase in Short Interestmarketbeat.com - January 15 at 2:56 AMShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Expands By 52.3%marketbeat.com - January 13 at 8:35 AMIs Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?finance.yahoo.com - January 11 at 8:48 AMImmix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Boardfinance.yahoo.com - January 4 at 10:11 AMImmix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Boardfinance.yahoo.com - December 18 at 1:12 PMInsider Spends US$267k Buying More Shares In Immix Biopharmafinance.yahoo.com - December 15 at 9:13 AMImmix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023finance.yahoo.com - December 11 at 2:02 PMImmix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summitfinance.yahoo.com - November 30 at 10:39 AMWhat Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'finance.yahoo.com - November 28 at 4:16 PMPleasing Signs As A Number Of Insiders Buy Immix Biopharma Stockfinance.yahoo.com - November 24 at 9:15 AMImmix to assess cell therapy in Phase Ib/IIa AL amyloidosis trialmsn.com - November 22 at 2:48 PMImmix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosisfinance.yahoo.com - November 22 at 2:48 PMFDA okays US clinical testing for Immix drug NXC-201msn.com - November 21 at 2:33 PMImmix Biopharma Announces FDA IND Clearance For CAR-T NXC-201markets.businessinsider.com - November 21 at 2:33 PMImmix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosingfinance.yahoo.com - November 21 at 2:33 PMImmix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patientsfinance.yahoo.com - November 6 at 1:05 PMImmix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patientsfinance.yahoo.com - November 6 at 1:05 PMHere's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Nowfinance.yahoo.com - October 31 at 12:34 PM Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.) Watch my video for all of the details IMMX Media Mentions By Week IMMX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMX News Sentiment▼0.000.43▲Average Medical News Sentiment IMMX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMX Articles This Week▼01▲IMMX Articles Average Week Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Celularity News Today Reneo Pharmaceuticals News Today Clene News Today Eledon Pharmaceuticals News Today Jaguar Health News Today Lantern Pharma News Today Kezar Life Sciences News Today Annovis Bio News Today BioLineRx News Today Eagle Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
